<?xml version="1.0" encoding="UTF-8"?><rss version="0.92">
<channel>
	<title>DWS Pill Scribe</title>
	<link>http://www.dancewithshadows.com/pillscribe</link>
	<description>The best of pharma news and views</description>
	<lastBuildDate>Sun, 26 Sep 2010 10:03:30 +0000</lastBuildDate>
	<docs>http://backend.userland.com/rss092</docs>
	<language>en</language>
	<!-- generator="WordPress/3.1" -->

	<item>
		<title>Gujarat&#8217;s new policy allows taller hospitals and hotels</title>
		<description><![CDATA[The Gujarat government has announced big concessions to hospitality and health care industries and have allowed a floor space index that can go up to 4 against the 1.8 that exists now for hospital and hotel projects. This means that new hotels and hospitals will be allowed to go up to height of 70 meters [...]]]></description>
		<link>http://www.dancewithshadows.com/pillscribe/gujarats-new-policy-allows-taller-hospitals-and-hotels/</link>
			</item>
	<item>
		<title>Natco Pharma to launch thalidomide drug lenalidomide (Revlimid) for myeloma in US</title>
		<description><![CDATA[Indian generic firm Natco Pharma has sought US FDA&#8217;s permission to market a low-cost version of the thalidomide based medicine Revlimid to treat multiple myeloma. Revlimid marketed by Celgene Corporation contains lenalidomide, a derivative of thalidomide. Besides multiple myeloma, lenalidomide is used in the treatment of the class of hematological disorders known as myelodysplastic syndromes [...]]]></description>
		<link>http://www.dancewithshadows.com/pillscribe/natco-pharma-to-launch-thalidomide-drug-lenalidomide-revlimid-for-myeloma-in-us/</link>
			</item>
	<item>
		<title>AAD-2004 to treat Alzheimer&#8217;s, Parkinson&#8217;s and lateral sclerosis coming</title>
		<description><![CDATA[AAD-2004, an experimental drug which claims to treat major neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS), may be around the corner. Developed by the Korean firm Neurotech Pharmaceuticals Co., Ltd, AAD-2004 has both anti-oxidative and anti-inflammatory activities. AAD-2004 has a dual function reducing free radicals and PGE2. Oxidative [...]]]></description>
		<link>http://www.dancewithshadows.com/pillscribe/aad-2004-to-treat-alzheimers-parkinsons-and-lateral-sclerosis-coming/</link>
			</item>
	<item>
		<title>Cesarean deliveries take a peak among first-time mothers in US</title>
		<description><![CDATA[One in every three first-time pregnant women in US is having cesarean delivery, according to a new study. To arrive at this conclusion, researchers from the Consortium on Safe Labor studied data on cesarean delivery from nearly 229,000 electronic medical records from 19 hospitals throughout the United States. 30.5 percent of all deliveries were done [...]]]></description>
		<link>http://www.dancewithshadows.com/pillscribe/cesarean-deliveries-take-a-peak-among-first-time-mothers-in-us/</link>
			</item>
	<item>
		<title>Antiplatelet drug atoxapar cuts blood clotting without bleeding risk: Eisai</title>
		<description><![CDATA[Atopaxar, a new drug being developed by Japanese drugmaker Eisai, could cut blood clotting in cardiovascular diseases without serious risks of bleeding that is common with the current antiplatelet therapies. Code-named as E5555, atopaxar has been found significantly cutting down deaths from cardiovascular diseases like heart attacks, strokes, studies have shown. Atopaxar is a protease-activated [...]]]></description>
		<link>http://www.dancewithshadows.com/pillscribe/antiplatelet-drug-atoxapar-cuts-blood-clotting-without-bleeding-risk-eisai/</link>
			</item>
	<item>
		<title>Shasun to develop Nanoparticle Biochem&#8217;s nano drug NBI-29 for prostate cancer</title>
		<description><![CDATA[India&#8217;s Shasun Pharmaceuticals has entered into a collaboration with Nanoparticle Biochem, Inc. (NBI) to develop a nanoparticle radioactive medicine NBI-29 to treat prostate cancer. NBI-29 is a gold-based, radioactive to be administered as a brachytherapeutic agent. This nanoparticle has been found having very good anti-tumour activities in prostate cancer. Early studies using NBI-29 nanoparticle drug [...]]]></description>
		<link>http://www.dancewithshadows.com/pillscribe/shasun-to-develop-nanoparticle-biochems-nano-drug-nbi-29-for-prostate-cancer/</link>
			</item>
	<item>
		<title>OGX-011 doubles life expectancy in advanced prostate cancer patients</title>
		<description><![CDATA[OGX-011, an experimental anti-clusterin agent, could almost double the life expectancy of patients with advanced prostate cancer, says a Canadian study. OGX-011 works against prostate cancer by blocking the production of a gene protein called clusterin. Clustering makes malignant prostate cells immune to drug treatments or radiation. OGX-011 could well be effective in certain other [...]]]></description>
		<link>http://www.dancewithshadows.com/pillscribe/ogx-011-doubles-life-expectancy-in-advanced-prostate-cancer-patients/</link>
			</item>
	<item>
		<title>India&#8217;s biotech market to touch $8 bn by 2015 growing at 20% yearly: CII-Yes Bank report</title>
		<description><![CDATA[India&#8217;s biotechnology sector is expected to touch as much as $8 billion growing at a pace of 20% per annum for the next five years, says a recent survey report  titled &#8216;India Life Sciences: Vision 2015&#8242; prepared by the Confederation of Indian Industries (CII) and Yes Bank Knowledge Report . Growing at CAGR of 20% per [...]]]></description>
		<link>http://www.dancewithshadows.com/pillscribe/indias-biotech-market-to-touch-8-bn-by-2015-growing-at-20-yearly-cii-yes-bank-report/</link>
			</item>
	<item>
		<title>New oral pill CH-4051 shows great promise in rheumatoid arthritis</title>
		<description><![CDATA[CH-4051, an oral therapy to treat rheumatoid arthritis developed by Chelsea Therapeutics, has shown promise in early phase trials. CH-4051 is the L-isomer of Chelsea&#8217;s pipeline drug CH-1504. It is an orally bioavailable, non-metabolized antifolate. CH-4051 has anti-inflammatory, autoimmune and anti-tumor properties that potently inhibit dihydrofolate reductase, an enzyme required for cell proliferation. CH-4051 has [...]]]></description>
		<link>http://www.dancewithshadows.com/pillscribe/new-oral-pill-ch-4051-shows-great-promise-in-rheumatoid-arthritis/</link>
			</item>
	<item>
		<title>India&#8217;s Glenmark to test new pain drug GRC 17536 on humans by 2011</title>
		<description><![CDATA[India&#8217;s Glenmark Pharma may soon start human testing of its a new pain drug lead compound code-named GRC 17536, the company announced. GRC 17536 is a novel chemical entity (NCE) which targets TRPA1 receptor antagonists for pain and respiratory disorders. A member of Transient Receptor Potential (TRP) family of ion channels, TRPA1 plays a key [...]]]></description>
		<link>http://www.dancewithshadows.com/pillscribe/indias-glenmark-to-test-new-pain-drug-grc-17536-on-humans-by-2011/</link>
			</item>
</channel>
</rss>

